Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences reports company developments around dermatology medical devices for in-office treatment of psoriasis, vitiligo, acne and other dermatologic conditions. Updates commonly address the XTRAC® 308 nm excimer laser, VTRAC® lamp systems, the TheraClear®X Acne Therapy System, clinical evidence for targeted UVB and photopneumatic therapies, and customer adoption by dermatology practices and academic medical centers.
Company news also covers financial results, recurring revenue and equipment sales, reimbursement and CPT coding for excimer laser treatments, international regulatory clearances such as COFEPRIS for TheraClearX in Mexico, and corporate-status events. In 2026, STRATA confirmed suspension of its common stock from The Nasdaq Capital Market and SEC filings to remove and terminate Exchange Act registration.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced preliminary first-quarter 2023 revenue estimates between $7.3 million and $7.8 million, marking the strongest results for the period since 2016. The company successfully placed 44 TheraClear®X devices, contributing to over 3,000 treatments sold since the product's launch in January 2023. Moreover, STRATA has converted 86 Pharos® accounts to XTRAC® devices, enhancing its presence in the eczema-laser market. CEO Bob Moccia expressed optimism about the sales momentum and its anticipated impact on revenues for 2023. The unaudited results are subject to revision, with full financial results expected in May 2023.
STRATA Skin Sciences, a medical technology firm, reported a record revenue of $36.2 million for 2022, up 21% from 2021, with fourth-quarter revenue at $10.6 million (17% increase year-over-year). Global recurring revenue reached $23 million for the year. Despite these gains, the company posted a net loss of $5.5 million for 2022 compared to a $2.7 million loss in 2021. The installed base of XTRAC® devices rose to 909. Looking forward, STRATA projects revenue in 2023 to be between $38 million and $40 million. The company aims to grow its market share while launching new marketing initiatives.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology firm focused on dermatologic treatments, will release its fourth-quarter 2022 financial results and Form 10-K on March 31, 2023. The company will hold a conference call at 8:30 AM EDT on the same day to discuss financial results and provide a corporate update. Key products include the XTRAC® and Pharos® excimer lasers, VTRAC® lamp systems, and the new TheraClear® X Acne Therapy System. STRATA operates a unique Partnership Program whereby practices are charged per treatment rather than for equipment purchases, ensuring support and marketing assistance.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced it will release its fourth quarter 2022 financial results on March 28, 2023, at 4:30 PM EDT. A conference call will be conducted to discuss the results and provide a corporate update. Interested parties can join the call using the numbers provided or view the webcast. STRATA specializes in products for treating dermatologic conditions such as psoriasis and acne.
STRATA Skin Sciences (NASDAQ: SSKN) has confirmed it has no financial ties or exposure to Silicon Valley Bank, stating that it does not hold cash deposits or securities with the bank. The company is focused on developing and marketing innovative dermatologic treatment technologies, including the XTRAC® and Pharos® lasers, as well as the TheraClear®X Acne Therapy System. STRATA utilizes a Partnership Program to provide in-office treatment options, emphasizing a service-oriented approach over traditional equipment purchases.